AskAwayHealth’s Post

𝐁𝐚𝐲𝐞𝐫 𝐒𝐮𝐛𝐦𝐢𝐭𝐬 𝐍𝐃𝐀 𝐟𝐨𝐫 𝐄𝐥𝐢𝐧𝐳𝐚𝐧𝐞𝐭𝐚𝐧𝐭 𝐟𝐨𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐟 𝐕𝐚𝐬𝐨𝐦𝐨𝐭𝐨𝐫 𝐒𝐲𝐦𝐩𝐭𝐨𝐦𝐬 𝐢𝐧 𝐌𝐞𝐧𝐨𝐩𝐚𝐮𝐬𝐞 Bayer Bayer has submitted a New Drug Application (NDA) to the FDA for elinzanetant, aimed at treating moderate to severe vasomotor symptoms (VMS) associated with menopause. This submission is based on positive results from the Phase III OASIS 1, 2, and 3 studies. “Half of the world’s population will experience menopause, with 27 million women in the U.S. currently experiencing this transition. Many go without treatment due to gaps in awareness and limitations of available options,” said Christine Roth Christine Roth, EVP, Global Product Strategy and Commercialization at Bayer. “The FDA submission for elinzanetant marks a significant milestone in offering a new non-hormonal option for women.” Elinzanetant (120 mg orally once daily) significantly reduced the frequency and severity of moderate-to-severe VMS and demonstrated a favorable safety profile. Consistent improvements were seen across all key secondary endpoints, including sleep disturbances and menopause-related quality of life. The full results of OASIS 1 and 2 were presented at the 2024 ACOG Annual Clinical & Scientific Meeting. Positive topline results for OASIS 3 were announced in March 2024, with further details to be presented at an upcoming scientific meeting. Bayer will also submit applications for marketing authorizations to other health authorities worldwide. #Bayer #Pharma #WomensHealth #Menopause #VasomotorSymptoms #Elinzanetant #HotFlashes #FDA #DrugDevelopment #ClinicalTrials #HealthcareInnovation #Pharmaceuticals #HealthAwareness #OASISStudies

Join OMA and Dr. Angela Fitch tonight for a FREE webinar: Managing the Complexity of Obesity During Menopause, sponsored by Currax Pharmaceuticals. Dr. Fitch will discuss the unique health challenges and conditions that affect women during menopause, focusing on the latest evidence characterizing the complexity and chronicity of obesity in these patients. Learn more and register now at https://bit.ly/4fzYHm0 #Obesity #ObesityTreatment #Menopause #WomensHealth

Menopause is a transformative stage in a woman's life, but it often arrives with a fair share of challenges. Medical cannabis has emerged as a promising alternative therapy that targets symptoms like insomnia, mood swings, and skin irritation by interacting with the body’s endocannabinoid system. A recent study highlighted that around 79% of women found medical cannabis effective in relieving menopause symptoms, including improvements in mood and anxiety. This significant endorsement shows the potential of medical cannabis as a viable treatment option. At Cantourage Clinic, we believe in empowering women by providing knowledge and solutions for managing menopause symptoms effectively. Join us as we embrace a new era of health and wellness for women everywhere. Find out more about How Medical Cannabis can work for Menopause and Perimenopause: https://lnkd.in/eawtDnVg #MenopauseAwarenessDay #MedicalCannabis #WomenHealth #MenopauseAwareness   https://lnkd.in/gdzxPNuu

🔥 Hot flashes feeling a bit too hot to handle?🌡️🥵 While menopause drugs may offer a quick fix, the FDA has raised serious concerns about potential liver damage. 😱 In my latest article, I break down the risks and what every woman should know before taking these meds. 👉 Discover the potential side effects 👉 Learn about FDAs recommendations 👉 Get informed to make the best choices for your health! Don't miss out—read the full article here at MedBound Times #hotflashes #menopause #Fezolinetant #Veozah https://lnkd.in/d7NEDG9j

GoodRx Launches Affordable Therapies and Savings Guide for Women in Menopause : #news - GoodRx has introduced new menopause treatments from Pfizer, along with a comprehensive guide on menopause medication savings for patients, as per a recent announcement. Patients with prescriptions who meet eligibility criteria can now access affordable menopause therapies at over ... Read More ▶️ https://buff.ly/4fhHbCN 💡 #aiinmenopause #goodrx #MedPulseAI #AIinHealthcare #AIinMedicine

More and more scientific studies are confirming the benefits of cannabis-related relief during menopause. https://lnkd.in/eXJuZEy5 hashtag#menopauseawareness hashtag#menopausesupport hashtag#menopauserelief hashtag#menopausehealth hashtag#menopause hashtag#NaturalWellness hashtag#MenopauseSupport hashtag#MenopauseRelief

This year's World Menopause Day's theme is MHT - Menopause Hormone Treatment - commonly known as HRT in the UK. So just a timely reminder that if you are prescribed HRT in the UK, you can apply for a prescription prepayment certificate specifically for HRT. This costs £19.80 for the year, and allows as many items of eligible HRT to be prescribed for the one cost. This is a huge saving compared to paying monthly and per medication. If you already have another medication prescribed such as a statin, then it might be cheaper to consider a yearly prepayment certificate that covers all medications. You can take a look on the link below as well as seeing which HRT medications are eligible for prescribing via this scheme. https://lnkd.in/ee_6AV_9

Can you afford not to have a menopause plan within your business? Even if you have less than 250 employees? The answer is no. I am qualified to explain the medical and pharmaceutical facts, not the fiction behind peri/menopause, and how to both help your company and colleagues. Find out about the tailored presentations/training I can deliver, as well as the 1:1 support I can offer to help you through this challenging stage of life with new found determination and knowledge. Contact me to find out how to increase staff retention, reduce sick leave, and increase staff satisfaction and wellbeing. @menopausefact.notfiction #menopausefact.notfiction #menopause #leadbetter #menopauseeducation #menopausesupport

This is significant news: Eli Lilly has removed BMI ranges from Zepbound's FDA label, following Novo's similar move with Wegovy earlier this year. Why does this matter? Because BMI is an outdated and oversimplified metric that shouldn't be the sole gatekeeper for accessing these medications. At Midi Health, we've long recognized that healthcare decisions need to be based on comprehensive patient evaluation, not just a number on a scale. Weight management, particularly during menopause, is complex and deeply individual. A one-size-fits-all BMI cutoff simply doesn't make sense. This label change empowers physicians to have more nuanced conversations with their patients and make treatment decisions based on individual health needs, circumstances, and goals. That's exactly how medicine should work. This shift from rigid BMI requirements to more personalized care approaches is something we've championed at Midi from day one. It's validating to see major pharmaceutical companies and the FDA moving in this direction too.

Weight gain in menopause is one of the most common complaints according to our patient quality of life intake questionnaire. Treating menopause symptoms with estrogen or non-hormonal therapeutics is always a necessary first step toward weight management. If someone is hot, not sleeping, and fatigued, they reach for the wrong foods to fuel their body and skip exercise. Many women experience food noise and need the help of medication to manage weight. MyMenopauseRx evaluates each patient as a unique individual, creating a personalized treatment plan that may include the use of FDA-approved GLPs. This recent warning from the FDA is an example of why MyMenopauseRx has chosen to put our patients' health first, saying no to prescribing compounded injectables. The Obesity Medicine Association itself issued a statement that is available to read in full on its website. Here is an excerpt: "To be clear, the only FDA-approved manufacturers of these medications are the companies that created the active pharmaceutical ingredients—Novo Nordisk and Eli Lilly. These companies stated that they do not sell the active ingredient to compounding pharmacies, and substances made or distributed by compounding pharmacies or other healthcare practitioners that claim to be semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound, Mounjaro) have not been reviewed by the FDA for safety, quality, or efficacy. Worse yet, there are reports that these counterfeits may pose serious health risks because of impurities or other non-pharmaceutical additives due to lack of regulatory oversight. Therefore, we do not recommend the use of these alternatives. We do not recommend the use of these alternatives". Sadly many patients do not know that FDA-approved Tirzepatide, Zepbound is only about $411/month (that includes the syringes) cash pay and is readily available. MyMenopauseRx patients are using it and SAFELY losing weight. MyMenopauseRx will continue its mission of improving access to women's menopause care that is safe, rooted in science, and covered by health insurance. Women deserve to feel their best at any age. 💜 #menopausecare #menopause #weightmanagement #zebound #telemedicine Michelle Corcoran